pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$TNYATenaya Therapeutics, Inc.

$TNYA
South San Francisco, CA, USupdated 13d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 1: 1Phase 2: 2
1Phase 12Phase 2
Phase 2
TN-201
Hypertrophic Cardiomyopathy
Phase 2
TN-401
Cardiomyopathy
Phase 1
TN-301
Diastolic Heart Failure (HFpEF)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCMrecruitingn=30
  • phase1Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVCrecruitingn=15
  • —Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathyrecruitingn=200
  • —Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)recruitingn=200

Insider activity

source: SEC Form 4

open-market buys + sells

  • Feb 25, 26SELLCOLUMN GROUP III GP, LP· 10% owner1,862,545 sh @ $0.56−$1.05M↗
  • Feb 25, 26SELLCOLUMN GROUP III GP, LP· 10% owner1,649,281 sh @ $0.56−$928K↗
  • Feb 24, 26SELLCOLUMN GROUP III GP, LP· 10% owner349,212 sh @ $0.62−$215K↗
  • Feb 24, 26SELLCOLUMN GROUP III GP, LP· 10% owner309,228 sh @ $0.62−$190K↗
  • Feb 23, 26SELLCOLUMN GROUP III GP, LP· 10% owner162,291 sh @ $0.60−$97K↗
  • Feb 23, 26SELLCOLUMN GROUP III GP, LP· 10% owner143,709 sh @ $0.60−$86K↗
  • Feb 20, 26SELLCOLUMN GROUP III GP, LP· 10% owner277,769 sh @ $0.61−$171K↗
  • Feb 20, 26SELLCOLUMN GROUP III GP, LP· 10% owner245,965 sh @ $0.61−$151K↗
  • Feb 17, 26SELLAli Faraz· Chief Executive Officer5,851 sh @ $0.64−$4K↗
  • Feb 17, 26SELLAli Faraz· Chief Executive Officer5,032 sh @ $0.64−$3K↗
  • Feb 17, 26SELLAli Faraz· Chief Executive Officer3,979 sh @ $0.64−$3K↗
  • Feb 17, 26SELLHiga Tomohiro· SVP, Finance2,022 sh @ $0.64−$1K↗
  • Feb 17, 26SELLTingley Whittemore· Chief Medical Officer1,876 sh @ $0.64−$1K↗
  • Feb 17, 26SELLTingley Whittemore· Chief Medical Officer1,642 sh @ $0.64−$1K↗
  • Feb 17, 26SELLTingley Whittemore· Chief Medical Officer1,642 sh @ $0.64−$1K↗
  • Feb 17, 26SELLHiga Tomohiro· SVP, Finance836 sh @ $0.64−$538↗
  • Feb 17, 26SELLHiga Tomohiro· SVP, Finance611 sh @ $0.64−$393↗
🐶 Hiring Signal
No open roles indexed yet — view Tenaya Therapeutics, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$TNYA
SEC CIK
0001858848
country
US
source
sec_tickers
top tags
Cardiology3Duchenne Muscular Dystrophy1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?